Skip to main content

Table 1 Prevalence of elevated triglycerides and atherogenic dyslipidemia in the general population and high-risk patient groups

From: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

Population Elevated triglycerides (TG) Atherogenic dyslipidemia
Criterion Prevalence Criteria Prevalence
General populations
 Europe [26] > 2.2 mmol/L 23.0% (8316/36,160) TG > 2.2 mmol/L + HDL-C < 1.0 mmol/L (treatment not specified) 6.0% (2169/36,160)
  On statin [26] > 2.2 mmol/L 30.0% (10,848/36,160)   
 USA [28, 30]
  Not on statin ≥ 2.26 mmol/L 11.9% (21.5 M/181.0 M)* TG ≥ 2.26 mmol/L + HDL-C < 1.0 mmol/L (treatment not specified) 6.6% (13.1 M/199.1 M)*
  On statin ≥ 2.26 mmol/L 15.4% (6.0 M/38.9 M)*   
High risk populations
 Primary prevention + risk factors [31] ≥ 2.3 mmol/L 20.8% (1591/7641) Elevated TG + HDL-C < 1.0 mmol/L 9.9% (759/7641)
 With T2DM [31] ≥ 2.3 mmol/L 27.5% (562/2046) Elevated TG + HDL-C < 1.0 mmol/L 14.9% (305/2046)
 Clinical ASCVD [29, 32] > 1.7 mmol/L 34.7% (2938/8467) TG > 2.0 mmol/L + HDL-C < 1.0 mmol/L in men, < 1.2 mmol/L in women 13–14%**
  1. ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; M, million; T2DM, type 2 diabetes mellitus; *, projected data; **, Czech component of EUROASPIRE (n = 1484, 1152 men and 332 women)